𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Characterisation of a linear binding site for a monoclonal antibody to hepatitis B core antigen

✍ Scribed by Matti Sällberg; Ulla Rudén; Lars O. Magnius; Hans P. Harthus; Michael Noah; Britta Wahren

Publisher
John Wiley and Sons
Year
1991
Tongue
English
Weight
443 KB
Volume
33
Category
Article
ISSN
0146-6615

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

The complete amino acid (aa) sequence of the hepatitis B virus (HBV) core protein (HBcAg), ayw subtype, was synthesized as decapeptides with five overlapping aas. The peptides were tested for reactivity with monoclonal antibodies (mAbs) to HBcAg (35/312, 37/275, and 7/275). All the mAbs specifically inhibited human anti‐HBc by cross competition in assays for anti‐HBc and anti‐HBe.

The mAb 35/312 recognised a peptide covering residues 76–85 of the HBcAg sequence. The other two mAbs did not react specifically with any linear peptide, suggesting discontinuous epitopes for these mAbs. The linear sequence EDPASR at residues 77–82 was found to constitute the epitope for mAb 35/312 when fine mapping the binding site. The most essential aas for mAb 35/312 were found to be the DP at residues 79–80, when peptides were synthesized where the aas at 77–83, were substituted by the other 19 aas. Since the mAb 35/312 inhibits the binding of human anti‐HBc positive sera, which are known to recognise an SDS labile epitope, the sequence 77–82 might be a part of a larger discontinuous epitope. Alternatively the mAb 35/312 blocks the binding of human anti‐HBc by steric hindrance.

📜 SIMILAR VOLUMES

Prospective assessment of donor blood sc
Prospective assessment of donor blood screening for antibody to hepatitis B core antigen as a means of preventing posttransfusion non-A, non-B, hepatitis
✍ Melchor Hoyos; José V. Sarrión; Teresa Pérez-Castellanos; Martín Prieto; María L 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 353 KB 👁 1 views

heart surgery at out institution were prospectively studied. Inclusion crit,eria were the following: absence of transfusion or acute hepatitis during the prior year, alcohol intake <80 gm per day. absence of the use of hepatotoxic drugs, normal aminotransferase values and negative hepatitis B virus

Improved serodiagnosis of non-A, non-B h
Improved serodiagnosis of non-A, non-B hepatitis by an assay detecting antibody to hepatitis C virus core antigen
✍ Tohru Katayama; Toshio Mazda; Shu Kikuchi; Shizuko Harada; Yoshiharu Matsuura; J 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 493 KB 👁 1 views

We examined sequential serum samples from 12 patients with well-characterized posttransfusion non-A, non-B hepatitis who had an acute, resolving self-limited type of clinical course for the presence of antibody to the hepatitis C virus nucleocapsid (core) protein (p22) expressed by a recombinant bac

Hepatitis B virus prevention strategies
Hepatitis B virus prevention strategies for antibody to hepatitis B core antigen–positive liver donation: A survey of North American, European, and Asian-Pacific transplant programs
✍ Robert Perrillo 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 169 KB

Prophylactic therapy is generally used to prevent reactivated hepatitis B after transplantation of an antibody to hepatitis B core antigen (anti-HBc)-positive liver. To gain insight into current practice, a questionnaire was e-mailed to 89 liver transplant physicians in the United States, Europe, an